Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Zymeworks Inc. (ZYME) Insider Trading Activity
Healthcare • Biotechnology • 290 employees
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Total Value
$13,133,244.99
Total Shares
1,109,777
Average Trade Value
$571,010.65
Most Active Insider
Eco R1 Capital, Llc
Total Activity: $14,420,459
Largest Single Transaction
$2,678,990
by Eco R1 Capital, Llc on Jan 10, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director, 10% Owner
|
Jan 17, 2025 | 19,748 | $273,998 | 15,720,161 (+0.1%) | Purchase | |
|
Director, 10% Owner
|
Jan 16, 2025 | 121,681 | $1,689,541 | 15,700,413 (+0.8%) | Purchase | |
|
Director, 10% Owner
|
Jan 15, 2025 | 39,029 | $546,671 | 15,578,732 (+0.3%) | Purchase | |
|
Director, 10% Owner
|
Jan 14, 2025 | 54,500 | $739,265 | 15,539,703 (+0.4%) | Purchase | |
|
Director, 10% Owner
|
Jan 13, 2025 | 74,125 | $992,875 | 15,485,203 (+0.5%) | Purchase | |
|
Director, 10% Owner
|
Jan 10, 2025 | 204,098 | $2,678,990 | 15,411,078 (+1.3%) | Purchase | |
|
Director, 10% Owner
|
Jan 8, 2025 | 21,021 | $295,829 | 15,206,980 (+0.1%) | Purchase | |
|
Chief Scientific Officer
|
Jan 6, 2025 | 9,792 | $146,137 | 14,741 (-66.4%) | Sale | |
|
Chief Scientific Officer
|
Jan 6, 2025 | 20,000 | $10,000 | 34,741 (+57.6%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 6, 2025 | 11,408 | $170,254 | 23,333 (-48.9%) | Sale | |
|
Chair CEO
|
Jan 6, 2025 | 33,406 | $498,554 | 80,803 (-41.3%) | Sale | |
|
EVP Chief Medical Officer
|
Jan 6, 2025 | 20,000 | $10,000 | 20,000 (+100.0%) | Exercise/Conversion | |
|
EVP Chief Medical Officer
|
Jan 6, 2025 | 11,110 | $165,807 | 8,890 (-125.0%) | Sale | |
|
Chair CEO
|
Jan 6, 2025 | 47,666 | $10,000 | 71,428 (+66.7%) | Exercise/Conversion | |
|
Chair CEO
|
Jan 6, 2025 | 23,885 | $356,462 | 47,543 (-50.2%) | Sale | |
|
Chair CEO
|
Jan 6, 2025 | 66,666 | $10,000 | 114,209 (+58.4%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 6, 2025 | 17,166 | $10,000 | 24,533 (+70.0%) | Exercise/Conversion | |
|
Director, 10% Owner
|
Jan 2, 2025 | 157,880 | $2,333,403 | 15,185,959 (+1.0%) | Purchase | |
|
Director, 10% Owner
|
Dec 31, 2024 | 146,501 | $2,134,446 | 15,028,079 (+1.0%) | Purchase | |
|
Director, 10% Owner
|
Dec 30, 2024 | 58,988 | $853,326 | 14,881,578 (+0.4%) | Purchase | |
|
Director, 10% Owner
|
Dec 27, 2024 | 101,659 | $1,473,181 | 14,822,590 (+0.7%) | Purchase | |
|
Director, 10% Owner
|
Dec 26, 2024 | 16,692 | $240,038 | 14,720,931 (+0.1%) | Purchase | |
|
Director, 10% Owner
|
Dec 24, 2024 | 11,958 | $168,896 | 14,704,239 (+0.1%) | Purchase |